Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Saved in:
Bibliographic Details
Published in:Blood 2022-11, Vol.140 (Supplement 1), p.2302-2305
Main Authors: Tournilhac, Olivier, Lecolant, Solene, Hacini, Maya, Bouabdallah, Krimo, Bailly, Sebastien, Laribi, Kamel, Belmondo, Thibaut, Maerevoet, Marie, Ysebaert, Loic, Guidez, Stéphanie, Le Gouill, Steven, Bonnet, Christophe, Andre, Marc, Dupuis, Jehan, Thieblemont, Catherine, Bachy, Emmanuel, Daguindau, Nicolas, Morschhauser, Franck, Tricot, Sabine, Feugier, Pierre, Banos, Anne, Lamy, Thierry, Chauchet, Adrien, Gyan, Emmanuel, Cartron, Guillaume, Farhat, Hassan, Camus, Vincent, Drenou, Bernard, Zerazhi, Hacene, Sibon, David, Nicolas-Virelizier, Emmanuelle, Delette, Caroline, Snauwaert, Sylvia, Straetmans, Nicole, Delarue, Richard, Parrens, Marie, Griolet, Samuel, Gaulard, Philippe, Delfau-Larue, Marie-Helene, De Leval, Laurence, Damaj, Gandhi Laurent
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-165217